返回 
加入收藏
新疆维吾尔族ACS患者CYP2C19基因多态性与氯吡格雷抗血小板反应性的相关性研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 新疆维吾尔族ACS患者CYP2C19基因多态性与氯吡格雷抗血小板反应性的相关性研究 |
| TITLE： | Study on the Correlation between CYP2C19 Gene Polymorphisms and Antiplatelet Reactivity of Clopidogrel in Xinjiang Uygur Patients with Acute Coronary Syndrome |
| 摘要： | 目的：探讨新疆维吾尔族急性冠脉综合征（ACS）患者CYP2C19基因多态性与氯吡格雷抗血小板反应性的相关性。方法：选取2018年1月－2019年1月新疆喀什地区第二人民医院心血管内科收治的维吾尔族ACS患者90例，予阿司匹林+氯吡格雷双联抗血小板治疗且出院后持续用药1年。检测患者血小板聚集抑制率（DPAI），评价其对氯吡格雷的反应性。采用聚合酶链式反应（PCR）-荧光探针法检测其CYP2C19*2、*3基因分型，采用PCR-直接测序法检测其CYP2C19*17基因分型。采用多因素Logistic回归分析探讨基因和非基因因素与患者DPAI的相关性。结果：90例患者中，氯吡格雷抵抗（CR）的患者有10例，非CR患者有80例。CYP2C19*2G/G、G/A、A/A型患者分别有58、28、4例，CYP2C19*3G/G、G/A型患者分别有88、2例，CYP2C19*17C/C、C/T型患者分别有64、26例，各基因型频率均符合Hardy-Weinberg平衡（P＞0.05）。治疗后，CYP2C19*2G/A、A/A型患者DAPI均较G/G型患者显著降低，且A/A型患者DAPI显著低于G/A型患者（P＜0.05）；CYP2C19*17C/T型患者DAPI较C/C型患者显著升高（P＜0.05）；而CYP2C19*3G/A与A/A型患者DAPI比较差异无统计学意义（P＞0.05）。多因素Logistic回归分析结果显示，CYP2C19基因多态性与新疆维吾尔族ACS患者DPAI独立相关[比值比＝2.314，95％置信区间（1.569，3.144），P＝0.009]，而年龄、性别、吸烟等非基因因素与DPAI无关（P＞0.05）。结论：CYP2C19基因多态性与新疆维吾尔族ACS患者氯吡格雷抗血小板反应性有关，*2野生型患者可能具有更高的DPAI，而*17野生型患者可能具有更低的DPAI。 |
| ABSTRACT： | OBJECTIVE：To investigate the correlation between CYP2C19 gene polymorphisms and antiplatelet reactivity of clopidogrel in Xinjiang Uygur patients with acute coronary syndrome （ACS）. METHODS ：Totally 90 Uygur patients with ACS who were admitted to the cardiovascular department of Xinjiang Kashi Second People ’s Hospital from Jan. 2018 to Jan. 2019 were selected as the study subjects. They were given anti-platelet therapy of asprin+clopidogrel ，and received the treatment continuously for one year after discharge. The platelet aggregation inhibition （DPAI）rate of the patients were determined ，and the response to clopidogrel was evaluated. PCR-fluorescence probe method was used to detect genotype of CYP2C19*2 and * 3，and PCR-direct sequencing method was used to detect genotype of * 17. Multivariate Logistic regression analysis was adopted to investigate the correlation of gene and non-gene factors with DPAI of patients. RESULTS ：Among 90 patients，there were 10 patients with clopidogrel resistance （CR）and 80 patients with non-CR. There were 58，28 and 4 patients with CYP2C19*2 G/G，G/A，A/A genotype，respectively；there were 88 and 2 patients with CYP2C19*3 G/G，G/A genotype ，respectively；there were 64 and 26 patients with CYP2C19*17 C/C，C/T genotype ，respectively；the genotype frequency of each genotype was consistent with Hardy-Weinberg equilibrium （P＞0.05）. After treatment ，DAPIs of patients with CYP2C19*2 G/A，A/A genotype were decreased significantly，while those of the patients with A/A genotype were significantly lower than patients with G/A genotype patients （P＜ 0.05）. DAPIs of patients with CYP2C19*17 C/T genotype were increased significantly ，compared with C/C genotype 2016D01C087） patients （P＜0.05）. There was no statistical significance in @fudan.edu.cn DAPIs between CYP2C19*3 G/A and A/A genotype patients （P＞0.05）. Multivariate Logistic regression analysis showed 85775264@qq.com that CYP2C19 gene pol ymorphism was independently related to DPAI in Xinjiang Uygur patients with ACS [OR ＝2.314，95％CI（1.569，3.144），P＝0.009]，while age ，gender，smoking and other non-gene factors were not related to DPAI （P＞0.05）. CONCLUSIONS ：CYP2C19 gene polymorphism is associated with antiplatelet reactivity of clopidogrel in Xinjiang Uygur patients with ACS. * 2 wild type patients may have higher DPAI ，while * 17 wild type patients may have lower DPAI. |
| 期刊： | 2020年第31卷第15期 |
| 作者： | 李治纲，韩彩平，郑丽丽，史迎新，古再丽努尔·阿卜杜柯尤木，刘珊珊 |
| AUTHORS： | LI Zhigang ，HAN Caiping ，ZHENG Lili，SHI Yingxin ，Guzailinuer·abudukeyoumu，LIU Shanshan |
| 关键字： | 氯吡格雷；CYP2C19；基因多态性；血小板聚集抑制率；急性冠脉综合征；维吾尔族 |
| KEYWORDS： | Clopidogrel；CYP2C19；Gene polymorphism ；Platelet aggregation inhibition rate ；Acute coronary syndrome ； |
| 阅读数： | 296 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
